Drug Profile
SBI 1997
Alternative Names: SBI1997Latest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Saronic Biotechnology
- Class Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; Liver cancer
Most Recent Events
- 21 Sep 2023 Saronic Biotechnology plans a phase I trial for Cancer (Late-stage disease) (Saronic Biotechnology pipeline, September 2023)
- 20 Sep 2023 Saronic Biotechnology plans to file an IND application for Cancer (Late-stage disease) (Saronic Biotechnology pipeline, September 2023)
- 18 Jul 2023 SBI 1997 is still in preclinical studies for Liver cancer in USA (Saronic Biotechnology pipeline, July 2023)